Literature DB >> 32523092

SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.

Ke Jiang1, Peng Liu2,3, Huizhe Xu1, Dapeng Liang1, Kun Fang1, Sha Du1, Wei Cheng1, Leiguang Ye4, Tong Liu5, Xiaohong Zhang1, Peng Gong2,3, Shujuan Shao6, Yifei Wang7, Songshu Meng8.   

Abstract

Triple-negative breast cancer (TNBC) is extremely aggressive and lacks effective therapy. SAM and SH3 domain containing1 (SASH1) has been implicated in TNBC as a candidate tumor suppressor; however, the mechanisms of action of SASH1 in TNBC remain underexplored. Here, we show that SASH1 was significantly downregulated in TNBC patients samples compared with other subtypes of breast cancer. Ectopic SASH1 expression inhibited, while depletion of SASH1 enhanced, the invasive phenotype of TNBC cells, accompanied by deregulated expression of MMP2 and MMP9. The functional effects of SASH1 depletion were confirmed in the chicken chorioallantoic membrane and mouse xenograft models. Mechanistically, SASH1 knockdown downregulated the phosphorylation levels of the Hippo kinase LATS1 and its effector YAP (Yes associated protein), thereby upregulating YAP accumulation together with its downstream target CYR61. Consistently, forced SASH1 expression exhibited opposite effects. Pharmacological inhibition of YAP or knockdown of YAP reversed the enhanced cell invasion of TNBC cells following SASH1 depletion. Furthermore, SASH1-induced YAP signaling was LATS1-dependent, which in reverse enhanced phosphorylation of SASH1. The SASH1 S407A mutant (phosphorylation deficient) failed to rescue the altered YAP signaling by SASH1 knockdown. Notably, SASH1 depletion upregulated ARHGAP42 levels via YAP-TEAD and the YAP-ARHGAP42-actin axis contributed to SASH1-regulated TNBC cell invasion. Therefore, our findings uncover a new mechanism for the tumor-suppressive activity of SASH1 in TNBC, which may serve as a novel target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32523092     DOI: 10.1038/s41388-020-1356-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

Review 1.  The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer.

Authors:  Chuan-bo Yao; Xin Zhou; Ce-shi Chen; Qun-ying Lei
Journal:  Yi Chuan       Date:  2017-07-20

2.  Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.

Authors:  M R Bubb; A M Senderowicz; E A Sausville; K L Duncan; E D Korn
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

3.  Promoter methylation assay of SASH1 gene in breast cancer.

Authors:  Lin Sheyu; Liu Hui; Zhang Junyu; Xu Jiawei; Wang Honglian; Sang Qing; Zhang Hengwei; Guo Xuhui; Xing Qinghe; He Lin
Journal:  J BUON       Date:  2013 Oct-Dec       Impact factor: 2.533

  3 in total
  8 in total

1.  GRHL2 Enhances Phosphorylated Estrogen Receptor (ER) Chromatin Binding and Regulates ER-Mediated Transcriptional Activation and Repression.

Authors:  Rebecca M Reese; Kyle T Helzer; Kaelyn O Allen; Christy Zheng; Natalia Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2022-08-29       Impact factor: 5.069

2.  Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.

Authors:  Xi Chen; Yixiao Yuan; Wenjun Ren; Fan Zhou; Xiaobin Huang; Jun Pu; Xiaoqun Niu; Xiulin Jiang
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

3.  Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).

Authors:  Damiano Cosimo Rigiracciolo; Nijiro Nohata; Rosamaria Lappano; Francesca Cirillo; Marianna Talia; Sendi Rafael Adame-Garcia; Nadia Arang; Simone Lubrano; Ernestina Marianna De Francesco; Antonino Belfiore; J Silvio Gutkind; Marcello Maggiolini
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

Review 4.  The biology of YAP in programmed cell death.

Authors:  Yifan Cheng; Misha Mao; Yong Lu
Journal:  Biomark Res       Date:  2022-05-23

5.  SUFU suppresses ferroptosis sensitivity in breast cancer cells via Hippo/YAP pathway.

Authors:  Kun Fang; Sha Du; Dachuan Shen; Zhipeng Xiong; Ke Jiang; Dapeng Liang; Jianxin Wang; Huizhe Xu; Lulu Hu; Xingyue Zhai; Yuting Jiang; Zhiyu Xia; Chunrui Xie; Di Jin; Wei Cheng; Songshu Meng; Yifei Wang
Journal:  iScience       Date:  2022-06-16

Review 6.  The 3D in vivo chorioallantoic membrane model and its role in breast cancer research.

Authors:  Cynthia Kohl; Thiha Aung; Silke Haerteis; Atanas Ignatov; Olaf Ortmann; Thomas Papathemelis
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-05       Impact factor: 4.322

7.  HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer.

Authors:  Misha Mao; Yunlu Jia; Yongxia Chen; Jingjing Yang; Ling Xu; Xun Zhang; Jichun Zhou; Zhaoqing Li; Cong Chen; Siwei Ju; Linbo Wang
Journal:  Cell Death Dis       Date:  2022-04-22       Impact factor: 9.685

8.  A homozygous stop-gain variant in ARHGAP42 is associated with childhood interstitial lung disease, systemic hypertension, and immunological findings.

Authors:  Qifei Li; Michal Dibus; Alicia Casey; Christina S K Yee; Sara O Vargas; Shiyu Luo; Samantha M Rosen; Jill A Madden; Casie A Genetti; Jan Brabek; Catherine A Brownstein; Shideh Kazerounian; Benjamin A Raby; Klaus Schmitz-Abe; John C Kennedy; Martha P Fishman; Mary P Mullen; Joan M Taylor; Daniel Rosel; Pankaj B Agrawal
Journal:  PLoS Genet       Date:  2021-07-07       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.